Oragenics closes acquisition of Odyssey Health’s neurological assets
In preclinical animal trials, the asset showed an excellent safety profile, quick and widespread biodistribution throughout the brain,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Jan 24
In preclinical animal trials, the asset showed an excellent safety profile, quick and widespread biodistribution throughout the brain,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Dec 23
The acquisition adds RayzeBio’s differentiated actinium-based radiopharmaceutical platform, including a pipeline of multiple drug development programmes to BMS’s…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Dec 23
The acquisition will strengthen AstraZeneca’s vaccines and immune therapies pipeline with Icosavax’s lead investigational vaccine candidate IVX-A12, a…
12 Dec 23
The merger will combine Sigma’s distribution infrastructure and CWG’s retailing know-how to create a full-service wholesaler, distributor, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
07 Dec 23
The proposed acquisition will include Cerevel’s clinical-stage pipeline of assets focused on psychiatric and neurological disorders, which will…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Dec 23
Through the acquisition, Roche will get access to Carmot’s portfolio of incretins, including its lead asset CT-388, along…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Dec 23
Through the acquisition of ImmunoGen for a total equity value of around $10.1bn, AbbVie is enabled to advance…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Nov 23
Under the agreement, Merck will acquire all the outstanding shares of Massachusetts-based Caraway with earnout milestones related to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Nov 23
Astellas will obtain Propella’s lead candidate PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor intended for the treatment…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Nov 23
The deal is expected to strengthen Alfasigma's pipeline, including the addition of a novel fixed-dose combination that has…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates